Neil Gallagher - 10 Apr 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
10 Apr 2023
Net transactions value
+$4,837,500
Form type
4
Filing time
12 Apr 2023, 16:02:44 UTC
Next filing
09 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $4,837,500 +250,000 $19.35 250,000 10 Apr 2023 Common Stock 250,000 $19.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty five percent (25%) of the total number of shares underlying the option shall vest on April 10, 2024, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.